Latest Pharma Insights
Quick Listen: Scrip’s Five Must-Know Things
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
Rogaine Firm Kenvue’s Challenge Clips Ad Claims For Hims & Hers’ Compounded Hair Growth Drug
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Quick Listen: Scrip’s Five Must-Know Things
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
This week: Lilly study shows Zepbound's cost savings can outweigh its price; Roche's up-to-$2.3bn Hanmi muscle-sparing obesity deal; US approvals for Revolution's Rasonque in pancreatic cancer and Jazz's Ziihera in gastroesophageal cancer; and Teva and Viatris pivot from generics to novelty.
Scrip - August 31, 2026
US FDA Grants CorTec Second Breakthrough Device Designation For Brain-Computer Interface
CorTec said it received a second breakthrough device designation for its investigational Brain Interchange device for use to help people with non-progressive quadriplegia communicate. In April, the German BCI company received the same designation for use in stroke-related impairments.
Medtech Insight - August 30, 2026
CorTec said it received a second breakthrough device designation for its investigational Brain Interchange device for use to help people with non-progressive quadriplegia communicate. In April, the German BCI company received the same designation for use in stroke-related impairments.
Medtech Insight - August 30, 2026
Rogaine Firm Kenvue’s Challenge Clips Ad Claims For Hims & Hers’ Compounded Hair Growth Drug
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Kenvue challenge led National Advertising Division to question Hims & Hers’ use of “trust” as synonymous with “recommend” in claims for hair loss sprays and serums containing minoxidil, the active ingredient also in OTC topicals, and finasteride, available Rx.
HBW Insight - August 31, 2026
Apotex Addresses Tariffs As US-Canada Tensions Rise
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Following the recent threat of US tariffs on imported generics from 2028, Apotex’s management has spoken about the uncertainty that remains surrounding the measure - but at the same time, says it is aligned with the Trump administration on its underlying goals.
Generics Bulletin - August 28, 2026
Takeda Patent Suit Puts Early Entyvio Biosimilar Launches Under Pressure
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Takeda’s six-patent suit against Polpharma puts an early legal test in front of first-wave Entyvio biosimilar entrants, with both Polpharma and Alvotech targeting potential US approval in 2027.
Generics Bulletin - August 28, 2026
Mylan, Lannett Must Face Humana Jury On Generic Price-Fixing Claims
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
A US federal court has cleared Humana’s overarching conspiracy and multiple drug-specific claims against Mylan and Lannett for trial, setting up a September bellwether in the generic price-fixing multi-district litigation.
Generics Bulletin - August 28, 2026
Lupin Targets Bigger Global Role For Europe And Emerging Markets
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
In an exclusive interview, Lupin’s Thierry Volle describes how the firm is looking to roughly double its Europe and emerging markets business over five years, leaning on specialty care, selective biosimilars and complex generics.
Generics Bulletin - August 28, 2026
De-Risked Doesn’t Mean It’s A Safe Bet
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026
Big pharma's late-stage M&A is not delivering: across deals since 2021, only 12 of the 33 involving a de-risked asset generated a multiple above 1.0x. In nearly two-thirds of cases the consensus forecast value of the late-stage assets acquired was less than the price paid for the company.
In Vivo - August 29, 2026